.jpg)
.png)
Last Updated: Wednesday, 01-Apr-2020 00:00:00 EDT
Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
Last Updated: Monday, 30-Mar-2020 13:15:00 EDT
The NLA aims to provide its members with relevant information and tools to succeed in the frequently changing healthcare landscape. View the documents below for resources provided by NLA members. Check back later to view new resources.
In 2019, the Centers for Disease Control and Prevention reported that prevalence for both obesity and overweight have continued to rise over the last eight years and are at an all-time high for adults and adolescents.(1) Approximately two-thirds of US adults are either obese (31%) or overweight (35%). Approximately one-third of US adolescents in grades 9-12 are obese (15%) or overweight (16%).
Article By:
KEVIN C. MAKI, PhD, CLS, FACN, FNLA
Department of Applied Health Science
School of Public Health
Indiana University
Bloomington, IN
Midwest Biomedical Research
Addison, IL
MARY R. DICKLIN, PhD
Midwest Biomedical Research Addison, IL
MAYA BALAKRISHNAN, MD
Section of Gastroenterology & Hepatology Baylor College of Medicine
Houston, TX
DAVID R. NEFF, DO
Past President, Midwest Lipid Association Michigan State University
College of Osteopathic Medicine Associate Clinical Professor Department of Family & Community Medicine
Ingham Regional Medical Center Lansing, MI
In October of 2018, the American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with the National Lipid Association and other organizations, published evidence-based guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD).(1) Along with the guidelines, there was a Special Report summarizing the rationale and evidence base for the current quantitative risk assessment tools.(2) These newest iterations stre
Article By:
DOUGLAS JACOBY, MD, FNLA
Director, Penn Cardiology Penn Preventative Care Medical Director, Penn Presbyterian Heart and Vascular Pavilion
Associate Professor of Clinical Medicine Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
MICHAEL AYERS, MD
Fellow-in-Training, Post-Graduate Year 5 Cardiovascular Medicine,
University of Pennsylvania Philadelphia, PA
Cardiovascular disease (CVD) remains the leading cause of death for women in the United States.(1) Unique factors affecting a woman’s health contribute significantly to CVD risk, but historically were not always represented in major guidelines. Some of these factors include hormonal changes, the presence of gender-specific risk factors and comorbidities more frequently seen in women (e.g. rheumatoid arthritis and systemic lupus erythematosus).
Article By:
SASHA DE JESUS, MD
Internal Medicine
Lenox Hill Hospital
New York, NY
MERLE MYERSON, MD, EdD, FACC, FNLA
Director, Preventive Cardiology & Lipid Clinic Division of Cardiology
Bassett Medical Center
Cooperstown, NY
Diplomate, American Board of Clinical Lipidology
EUGENIA GIANOS, MD, FACC, FASE, FNLA
System Director, Cardiovascular Prevention Northwell Health
Director, Women’s Heart Health
Lenox Hill Hospital
New York, NY
Diplomate, American Board of Clinical Lipidology
Reduced estimated glomerular filtration rate (GFR) and chronic kidney disease (CKD) are also independently associated with the risk of death and cardiovascular (CV) events in community.(3) When compared to the general population, patients with CKD have a distinct lipid profile which involves alterations in different lipoprotein classes and shows considerable variations depending on the stage of CKD.(4) Although very complex, the most important characteristics of this uremic lipid profile can
Article By:
KAVEH REZAEI BOOKANI, MD
Fellow
NorthShore University Health System Chicago, IL
DAVID DAVIDSON, MD, FACC, FNLA
Director, Lipid Clinic
NorthShore University Health System Clinical Instructor
University of Chicago
Chicago, IL
Diplomate, American Board of Clinical Lipidology
MARLYS L. KOSCHINSKY, PhD, FNLA
Scientific & Executive Director, Robarts Research Institute Professor, Department of Physiology & Pharmacology Schulich School of Medicine & Dentistry
London, ON
The Midwest Lipid Association Chapter started the fall with our co-sponsored Clinic Lipid Update in Minneapolis in September. It was great to see many familiar NLA member colleagues as well as new attendees.
As part of the MWLA’s goals for this year, we are finalizing a three-year strategic plan. An important step was to create a mission statement.
Article By:
ANN LIEBESKIND, MD, FAAP, FNLA
President, Midwest Lipid Association
Faculty, Foundations of Lipidology Course
Founder, Mobile Health Team Lipids Clinic
Adjunct Assistant Professor of Pediatrics, University of Wisconsin School of Medicine and Public Health
Neenah and Wauwatosa, WI
Diplomate, American Board of Clinical Lipidology
Introduction
Elevated cholesterol is a well-known and modifiable risk factor for cardiovascular disease. Hyperlipidemia due to secondary causes is common and should be evaluated as part of treatment. Potential secondary causes include diabetes mellitus, excessive alcohol intake, cholestatic liver disease, hypothyroidism, chronic kidney disease, nephrotic syndrome and various classes of medications.(1)
Article By:
ABIGAIL F. RABATIN, PharmD, BCACP, CLS
Specialty Practice Pharmacist Ambulatory Care
The Ohio State University
Wexner Medical Center
Columbus, OH
KELLY M. BARTSCH, PharmD, BCPS, CLS
Specialty Practice Pharmacist Ambulatory Care
The Ohio State University
Wexner Medical Center Columbus, OH
ELISA M. BADDOUR, PharmD, BCACP
Primary Care Pharmacy Specialist
Cleveland Clinic
Cleveland, OH
LAXMI S. MEHTA, MD, FACC
Director of Preventative Cardiology & Women’s Cardiovascular Health Director of Lipid Clinics
Professor of Medicine
The Ohio State University
Wexner Medical Center Columbus, OH
Diplomate, American Board of Clinical Lipidology
Fabry’s Disease and Morquio A syndrome are two rare genetic diseases that lead to a diverse series of problems including cardiovascular.(1,30) Until recently, treatment options have been limited to treat these conditions. Now that there are available therapies to help improve quality and quantity of life, (20,46) it is important to be able to recognize these conditions in clinical practice to help initiate treatment earlier.
Article By:
MRINALI SHETTY, MD
Cardiology Fellow-In-Training
University of Chicago (NorthShore) Program Evanston, IL
DAVID DAVIDSON, MD, FACC, FNLA
Director, Lipid Clinic
NorthShore University Health System Clinical Instructor
University of Chicago
Chicago, IL
Results from multiple trials prompted the Food and Drug Administration’s (FDA) approval of empagliflozin (Jardiance) for reducing cardiovascular (CV) death and canagliflozin (Invokana) for reducing CV death and CV events, in patients with cardiovascular disease and type II diabetes (T2D).(1-6) The FDA’s expanded approval of empagliflozin and canagliflozin led to the American College of Cardiology (ACC) and the American Diabetes Association
Article By:
SARA LYNN PETERSON, PharmD
Complex Lipids Clinic
Mobile Health Team
Neenah, WI